Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
The human rotavirus live attenuated virus is a weakened form of the wild-type human rotavirus, used as an oral vaccine to prevent severe gastroenteritis in infants and young children. It replicates locally in the small intestine, stimulating mucosal and systemic immunity. Key antigens are VP7 (G-protein) and VP4 (P-protein) which induce neutralizing antibodies. Vaccines include Rotarix (monovalent, human strain) and RotaTeq (pentavalent, bovine/human reassortant).
Stimulates mucosal and systemic immunity through limited replication in the small intestine, leading to production of neutralizing antibodies (IgA and IgG) against viral proteins, particularly VP7 and VP4.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Human Rotavirus Live Attenuated Virus.